MREO News and Press, Mereo BioPharma Group From 03/24/21

Mereo BioPharma is a biopharma company focused on oncology and rare diseases, suiting a market cap of $388M USD at the time of this article. The company currently has great partnerships in place, which will increase the chances of success as well as my confidence as an investor. M...

MREO came to some prominence after Ultragenyx gave it a nice deal in December 2020. Its lead asset etigilimab has some early interesting data. It will take a few more years for the company to garner more investor interest. For further details see: Mereo BioPharma: Underf...

LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight,...

5 Biotech Penny Stocks Trending This Week In the past twelve months, biotech penny stocks have become all the rage. Regardless of whether they are working on a covid treatment, investors have shown a massive propensity for penny stocks in the biotechnology industry. The term biotech...

Gainers: [[EH]] +18.6%. [[VSTM]] +17.7%. [[CSOD]] +11.4%. [[SSP]] +10.93%. [[MREO]] +10.6%.Losers: [[MVIS]] -10.4%. [[EPSN]] -7.5%. [[BLCT]] -4.7%. [[DRVN]] -3.7%. [[FELE]] -3.4%. For further details see: EH, CSOD, MVIS and DRVN among after-hours movers

LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously annou...

Mereo BioPharma (MREO) traded 1.64% higher premarket after pricing its underwritten public offering of 34.5M ADSs at $2.90/ADS; underwriters granted 30-day option to purchase up to 5.18M additional ADSs.Each ADS represents five ordinary shares of Mereo.Gross proceeds are expected to...

LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritte...

LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that it intends to offer and ...

Gainers: [[ACY]] +39.4%. [[MREO]] +5.0%. [[SOAC]] +4.2%. [[GTHX]] +4.0%. [[STPK]] +3.4%.Losers: [[AIRT]] -23.1%. [[SCPS]] -9.4%. [[TRITW]] -6.8%. [[ID]] -6.0%. [[VET]] -4.9%. For further details see: ACY, MREO, AIRT and ID among after-hours movers